CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
نویسندگان
چکیده
Alessandro Rambaldi, Manuela Lazzari, Cristina Manzoni, Emanuela Carlotti, Luca Arcaini, Michele Baccarani, Tiziano Barbui, Carlo Bernasconi, Giuseppe Dastoli, Giovanna Fuga, Enrica Gamba, Livio Gargantini, Valter Gattei, Francesco Lauria, Mario Lazzarino, Franco Mandelli, Enrica Morra, Alessandro Pulsoni, Michela Ribersani, Pier Luigi Rossi-Ferrini, Maurizio Rupolo, Sante Tura, Vittorina Zagonel, Francesco Zaja, PierLuigi Zinzani, Gigliola Reato, and Robin Foa
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody that targets B-cell–specific antigen CD20 and an effective treatment for B-cell non-Hodgkin lymphoma. Although it is readily used in clinical practice, the exact mechanism of its antitumor effect is unclear. One potential mechanism involves complement-mediated cytotoxicity. It has been shown that rituximab induces complement-mediated cytotoxicity in f...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma
In follicular lymphoma, the t(14;18) status of the peripheral blood and bone marrow analyzed by polymerase chain reaction (PCR) is assumed to correlate with disease activity in patients with relapsed disease. The clinical significance of quantitating circulating lymphoma cells by realtime PCR is reported in patients on firstline treatment. Thirty-four consecutive patients with previously untrea...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule
The potential benefits of extended rituximab treatment have been investigated in a randomized trial comparing the standard schedule with prolonged treatment in 202 patients with newly diagnosed or refractory/relapsed follicular lymphoma (FL). All patients received standard treatment (rituximab 375 mg/m2 weekly 4). In 185 evaluable patients, the overall response rate was 67% in chemotherapynaive...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial
This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive nonHodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission ...
متن کاملIntravascular Lymphoma in the CNS: Options for Treatment
Purpose of review The purpose of this review was to discuss therapeutic manipulations and effective current interventions available to treat intravascular lymphoma in the central nervous system. Recent findings Patients experienced resolution and remission of disease for 14 months and up to 2 years after eight cycles of R-CHOP and four courses of intrathecal therapy with MTX, cytarabine, and pr...
متن کامل